Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Market Overview
1.1 Immuno-Oncology Product Introduction
1.2 Global Immuno-Oncology Market Size Forecast (2020-2031)
1.3 Immuno-Oncology Market Trends & Drivers
1.3.1 Immuno-Oncology Industry Trends
1.3.2 Immuno-Oncology Market Drivers & Opportunity
1.3.3 Immuno-Oncology Market Challenges
1.3.4 Immuno-Oncology Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Immuno-Oncology Players Revenue Ranking (2024)
2.2 Global Immuno-Oncology Revenue by Company (2020-2025)
2.3 Key Companies Immuno-Oncology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Immuno-Oncology Product Offered
2.5 Key Companies Time to Begin Mass Production of Immuno-Oncology
2.6 Immuno-Oncology Market Competitive Analysis
2.6.1 Immuno-Oncology Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Immuno-Oncology Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-Oncology as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immune Checkpoint Inhibitors
3.1.2 Cytokine-Based Immunotherapy
3.1.3 Cancer Vaccines
3.1.4 CAR-T Cell Therapy
3.1.5 Others
3.2 Global Immuno-Oncology Sales Value by Type
3.2.1 Global Immuno-Oncology Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Immuno-Oncology Sales Value, by Type (2020-2031)
3.2.3 Global Immuno-Oncology Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Drugstores
4.1.3 Others
4.2 Global Immuno-Oncology Sales Value by Application
4.2.1 Global Immuno-Oncology Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Immuno-Oncology Sales Value, by Application (2020-2031)
4.2.3 Global Immuno-Oncology Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Immuno-Oncology Sales Value by Region
5.1.1 Global Immuno-Oncology Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Immuno-Oncology Sales Value by Region (2020-2025)
5.1.3 Global Immuno-Oncology Sales Value by Region (2026-2031)
5.1.4 Global Immuno-Oncology Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Immuno-Oncology Sales Value, 2020-2031
5.2.2 North America Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Immuno-Oncology Sales Value, 2020-2031
5.3.2 Europe Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Immuno-Oncology Sales Value, 2020-2031
5.4.2 Asia Pacific Immuno-Oncology Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Immuno-Oncology Sales Value, 2020-2031
5.5.2 South America Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Immuno-Oncology Sales Value, 2020-2031
5.6.2 Middle East & Africa Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Immuno-Oncology Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Immuno-Oncology Sales Value, 2020-2031
6.3 United States
6.3.1 United States Immuno-Oncology Sales Value, 2020-2031
6.3.2 United States Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Immuno-Oncology Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Immuno-Oncology Sales Value, 2020-2031
6.4.2 Europe Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Immuno-Oncology Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Immuno-Oncology Sales Value, 2020-2031
6.5.2 China Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.5.3 China Immuno-Oncology Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Immuno-Oncology Sales Value, 2020-2031
6.6.2 Japan Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Immuno-Oncology Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Immuno-Oncology Sales Value, 2020-2031
6.7.2 South Korea Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Immuno-Oncology Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Immuno-Oncology Sales Value, 2020-2031
6.8.2 Southeast Asia Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Immuno-Oncology Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Immuno-Oncology Sales Value, 2020-2031
6.9.2 India Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
6.9.3 India Immuno-Oncology Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Profile
7.1.2 Bristol-Myers Squibb Main Business
7.1.3 Bristol-Myers Squibb Immuno-Oncology Products, Services and Solutions
7.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.1.5 Bristol-Myers Squibb Recent Developments
7.2 Merck & Co., Inc.
7.2.1 Merck & Co., Inc. Profile
7.2.2 Merck & Co., Inc. Main Business
7.2.3 Merck & Co., Inc. Immuno-Oncology Products, Services and Solutions
7.2.4 Merck & Co., Inc. Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.2.5 Merck & Co., Inc. Recent Developments
7.3 Roche AG
7.3.1 Roche AG Profile
7.3.2 Roche AG Main Business
7.3.3 Roche AG Immuno-Oncology Products, Services and Solutions
7.3.4 Roche AG Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.3.5 Roche AG Recent Developments
7.4 AstraZeneca, Plc
7.4.1 AstraZeneca, Plc Profile
7.4.2 AstraZeneca, Plc Main Business
7.4.3 AstraZeneca, Plc Immuno-Oncology Products, Services and Solutions
7.4.4 AstraZeneca, Plc Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.4.5 AstraZeneca, Plc Recent Developments
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Profile
7.5.2 Sanofi S.A. Main Business
7.5.3 Sanofi S.A. Immuno-Oncology Products, Services and Solutions
7.5.4 Sanofi S.A. Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.5.5 Sanofi S.A. Recent Developments
7.6 Dendreon Pharmaceuticals
7.6.1 Dendreon Pharmaceuticals Profile
7.6.2 Dendreon Pharmaceuticals Main Business
7.6.3 Dendreon Pharmaceuticals Immuno-Oncology Products, Services and Solutions
7.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.6.5 Dendreon Pharmaceuticals Recent Developments
7.7 Novartis
7.7.1 Novartis Profile
7.7.2 Novartis Main Business
7.7.3 Novartis Immuno-Oncology Products, Services and Solutions
7.7.4 Novartis Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.7.5 Novartis Recent Developments
7.8 Gilead Sciences Inc.
7.8.1 Gilead Sciences Inc. Profile
7.8.2 Gilead Sciences Inc. Main Business
7.8.3 Gilead Sciences Inc. Immuno-Oncology Products, Services and Solutions
7.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.8.5 Gilead Sciences Inc. Recent Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Profile
7.9.2 Merck KGaA Main Business
7.9.3 Merck KGaA Immuno-Oncology Products, Services and Solutions
7.9.4 Merck KGaA Immuno-Oncology Revenue (US$ Million) & (2020-2025)
7.9.5 Merck KGaA Recent Developments
8 Industry Chain Analysis
8.1 Immuno-Oncology Industrial Chain
8.2 Immuno-Oncology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Immuno-Oncology Sales Model
8.5.2 Sales Channel
8.5.3 Immuno-Oncology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

List of Tables
Table 1. Immuno-Oncology Market Trends
Table 2. Immuno-Oncology Market Drivers & Opportunity
Table 3. Immuno-Oncology Market Challenges
Table 4. Immuno-Oncology Market Restraints
Table 5. Global Immuno-Oncology Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Immuno-Oncology Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Immuno-Oncology Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Immuno-Oncology Product Type
Table 9. Key Companies Time to Begin Mass Production of Immuno-Oncology
Table 10. Global Immuno-Oncology Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-Oncology as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Immuno-Oncology Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Immuno-Oncology Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Immuno-Oncology Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Immuno-Oncology Sales Market Share in Value by Type (2020-2025)
Table 17. Global Immuno-Oncology Sales Market Share in Value by Type (2026-2031)
Table 18. Global Immuno-Oncology Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Immuno-Oncology Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Immuno-Oncology Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Immuno-Oncology Sales Market Share in Value by Application (2020-2025)
Table 22. Global Immuno-Oncology Sales Market Share in Value by Application (2026-2031)
Table 23. Global Immuno-Oncology Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Immuno-Oncology Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Immuno-Oncology Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Immuno-Oncology Sales Value by Region (2020-2025) & (%)
Table 27. Global Immuno-Oncology Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Immuno-Oncology Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Immuno-Oncology Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Immuno-Oncology Sales Value, (2026-2031) & (US$ Million)
Table 31. Bristol-Myers Squibb Basic Information List
Table 32. Bristol-Myers Squibb Description and Business Overview
Table 33. Bristol-Myers Squibb Immuno-Oncology Products, Services and Solutions
Table 34. Revenue (US$ Million) in Immuno-Oncology Business of Bristol-Myers Squibb (2020-2025)
Table 35. Bristol-Myers Squibb Recent Developments
Table 36. Merck & Co., Inc. Basic Information List
Table 37. Merck & Co., Inc. Description and Business Overview
Table 38. Merck & Co., Inc. Immuno-Oncology Products, Services and Solutions
Table 39. Revenue (US$ Million) in Immuno-Oncology Business of Merck & Co., Inc. (2020-2025)
Table 40. Merck & Co., Inc. Recent Developments
Table 41. Roche AG Basic Information List
Table 42. Roche AG Description and Business Overview
Table 43. Roche AG Immuno-Oncology Products, Services and Solutions
Table 44. Revenue (US$ Million) in Immuno-Oncology Business of Roche AG (2020-2025)
Table 45. Roche AG Recent Developments
Table 46. AstraZeneca, Plc Basic Information List
Table 47. AstraZeneca, Plc Description and Business Overview
Table 48. AstraZeneca, Plc Immuno-Oncology Products, Services and Solutions
Table 49. Revenue (US$ Million) in Immuno-Oncology Business of AstraZeneca, Plc (2020-2025)
Table 50. AstraZeneca, Plc Recent Developments
Table 51. Sanofi S.A. Basic Information List
Table 52. Sanofi S.A. Description and Business Overview
Table 53. Sanofi S.A. Immuno-Oncology Products, Services and Solutions
Table 54. Revenue (US$ Million) in Immuno-Oncology Business of Sanofi S.A. (2020-2025)
Table 55. Sanofi S.A. Recent Developments
Table 56. Dendreon Pharmaceuticals Basic Information List
Table 57. Dendreon Pharmaceuticals Description and Business Overview
Table 58. Dendreon Pharmaceuticals Immuno-Oncology Products, Services and Solutions
Table 59. Revenue (US$ Million) in Immuno-Oncology Business of Dendreon Pharmaceuticals (2020-2025)
Table 60. Dendreon Pharmaceuticals Recent Developments
Table 61. Novartis Basic Information List
Table 62. Novartis Description and Business Overview
Table 63. Novartis Immuno-Oncology Products, Services and Solutions
Table 64. Revenue (US$ Million) in Immuno-Oncology Business of Novartis (2020-2025)
Table 65. Novartis Recent Developments
Table 66. Gilead Sciences Inc. Basic Information List
Table 67. Gilead Sciences Inc. Description and Business Overview
Table 68. Gilead Sciences Inc. Immuno-Oncology Products, Services and Solutions
Table 69. Revenue (US$ Million) in Immuno-Oncology Business of Gilead Sciences Inc. (2020-2025)
Table 70. Gilead Sciences Inc. Recent Developments
Table 71. Merck KGaA Basic Information List
Table 72. Merck KGaA Description and Business Overview
Table 73. Merck KGaA Immuno-Oncology Products, Services and Solutions
Table 74. Revenue (US$ Million) in Immuno-Oncology Business of Merck KGaA (2020-2025)
Table 75. Merck KGaA Recent Developments
Table 76. Key Raw Materials Lists
Table 77. Raw Materials Key Suppliers Lists
Table 78. Immuno-Oncology Downstream Customers
Table 79. Immuno-Oncology Distributors List
Table 80. Research Programs/Design for This Report
Table 81. Key Data Information from Secondary Sources
Table 82. Key Data Information from Primary Sources
Table 83. Business Unit and Senior & Team Lead Analysts


List of Figures
Figure 1. Immuno-Oncology Product Picture
Figure 2. Global Immuno-Oncology Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Immuno-Oncology Sales Value (2020-2031) & (US$ Million)
Figure 4. Immuno-Oncology Report Years Considered
Figure 5. Global Immuno-Oncology Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Immuno-Oncology Revenue in 2024
Figure 7. Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. Immune Checkpoint Inhibitors Picture
Figure 9. Cytokine-Based Immunotherapy Picture
Figure 10. Cancer Vaccines Picture
Figure 11. CAR-T Cell Therapy Picture
Figure 12. Others Picture
Figure 13. Global Immuno-Oncology Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 14. Global Immuno-Oncology Sales Value Market Share by Type, 2024 & 2031
Figure 15. Product Picture of Hospitals
Figure 16. Product Picture of Drugstores
Figure 17. Product Picture of Others
Figure 18. Global Immuno-Oncology Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 19. Global Immuno-Oncology Sales Value Market Share by Application, 2024 & 2031
Figure 20. North America Immuno-Oncology Sales Value (2020-2031) & (US$ Million)
Figure 21. North America Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
Figure 22. Europe Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 23. Europe Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
Figure 24. Asia Pacific Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 25. Asia Pacific Immuno-Oncology Sales Value by Region (%), 2024 VS 2031
Figure 26. South America Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 27. South America Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
Figure 28. Middle East & Africa Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 29. Middle East & Africa Immuno-Oncology Sales Value by Country (%), 2024 VS 2031
Figure 30. Key Countries/Regions Immuno-Oncology Sales Value (%), (2020-2031)
Figure 31. United States Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 32. United States Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 33. United States Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 34. Europe Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 35. Europe Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 36. Europe Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 37. China Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 38. China Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 39. China Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 40. Japan Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 41. Japan Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 42. Japan Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 43. South Korea Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 44. South Korea Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 45. South Korea Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 46. Southeast Asia Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 48. Southeast Asia Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 49. India Immuno-Oncology Sales Value, (2020-2031) & (US$ Million)
Figure 50. India Immuno-Oncology Sales Value by Type (%), 2024 VS 2031
Figure 51. India Immuno-Oncology Sales Value by Application (%), 2024 VS 2031
Figure 52. Immuno-Oncology Industrial Chain
Figure 53. Immuno-Oncology Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed